腫瘍壊死因子阻害薬の世界市場レポート 2025年

腫瘍壊死因子阻害薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.0％で482億4,000万米ドルに成長します。予測期間の成長は、新興市場の成長、規制の変更と承認、個別化医療へのアプローチ、ヘルスケアに対する認識とアクセス、生物学的療法の進歩に起因すると考えられます。予測期間の主な動向には、患者中心のソリューション、実世界のエビデンスとデータ、安全性と副作用への注目、先進ドラッグデリバリーシステム、臨床応用の拡大などがあります。

自己免疫疾患の増加は腫瘍壊死因子阻害薬市場の成長を促進します。自己免疫疾患は、免疫系が誤って健康な人体組織を攻撃することを特徴とし、多くの場合、炎症、痛み、腫れを引き起こします。腫瘍壊死因子阻害薬は、炎症をブロックし、関連症状を緩和し、免疫系を安定させることにより、これらの影響を緩和する上で重要な役割を果たしています。2022年6月現在、自己免疫学会の報告によると、米国では470万人の男性が自己免疫疾患に罹患しており、自己免疫疾患患者全体の20％を占めています。さらに、2022年には米国で合計3,100万人が80～150種類の自己免疫疾患に罹患していると報告されており、今後さらに増加することが予想されます。その結果、自己免疫疾患の有病率の上昇が腫瘍壊死因子阻害薬市場の成長の原動力となっています。

ヘルスケア支出の増加が腫瘍壊死因子阻害薬市場の成長を牽引すると期待されています。ヘルスケア支出とは、特定の期間にヘルスケアサービス、製品、活動に費やされる総額のことで、個人、地域社会、国家、世界規模で測定することができます。ヘルスケア支出の増加は、TNF阻害剤のような生物学的製剤を含む、先進的で高価な治療へのアクセスが向上することとしばしば関連しています。例えば、2024年1月、米国の政府機関である国立衛生研究所は、2022年の米国のヘルスケア支出は4.1％増加し、4兆5,000億米ドルに達したと報告しました。この伸び率は、2021年に指摘された3.2％増を上回るものだった。したがって、医療費の増加は腫瘍壊死因子阻害薬市場の成長に寄与すると思われます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腫瘍壊死因子阻害薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の腫瘍壊死因子阻害薬市場：成長率分析
• 世界の腫瘍壊死因子阻害薬市場の実績：規模と成長, 2019-2024
• 世界の腫瘍壊死因子阻害薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界腫瘍壊死因子阻害薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腫瘍壊死因子阻害薬市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒュミラ
• エンブレル
• レミケード
• シンポニ/シンポニアリア
• シムジア
• バイオシミラー
• 世界の腫瘍壊死因子阻害薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下注射
• 静脈注射
• 世界の腫瘍壊死因子阻害薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の腫瘍壊死因子阻害薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 関節リウマチ
• 乾癬
• 乾癬性関節炎
• クローン病
• 潰瘍性大腸炎
• 強直性脊椎炎
• 若年性特発性関節炎
• 化膿性汗腺炎
• その他の用途
• 世界の腫瘍壊死因子阻害薬市場、ヒュミラのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒュミラ（アダリムマブ）
• 世界の腫瘍壊死因子阻害薬市場、エンブレルのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンブレル（エタネルセプト）
• 世界の腫瘍壊死因子阻害薬市場レミケードのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• レミケード（インフリキシマブ）
• 世界の腫瘍壊死因子阻害薬市場、シンポニまたはシンポニアリアのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シンポニ（ゴリムマブ）
• シンポニ・アリア
• 世界の腫瘍壊死因子阻害薬市場、Cimziaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シムジア（セルトリズマブペゴル）
• 世界の腫瘍壊死因子阻害薬市場、バイオシミラーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒュミラのバイオシミラー
• エンブレルのバイオシミラー
• レミケードのバイオシミラー
• シンポニのバイオシミラー
• シムジアのバイオシミラー

第7章 地域別・国別分析

• 世界の腫瘍壊死因子阻害薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腫瘍壊死因子阻害薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腫瘍壊死因子阻害薬市場：競合情勢
• 腫瘍壊死因子阻害薬市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Pfizer Inc.
• Samsung Bioepis Co. Ltd.
• Sanofi SA
• Merck & Co. Inc.
• Boehringer Ingelheim Pharmaceuticals
• Lupin Ltd.
• F. Hoffmann-La Roche AG
• Cadila Healthcare Ltd.
• Aryogen Biopharma
• Casi Pharmaceuticals
• Celltrion Inc.
• Bristol-Myers Squibb
• Dexa Medica
• Epirus Biopharmaceuticals
• Glaxosmithkline plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腫瘍壊死因子阻害薬市場2029：新たな機会を提供する国
• 腫瘍壊死因子阻害薬市場2029：新たな機会を提供するセグメント
• 腫瘍壊死因子阻害薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tumor necrosis factor (TNF) inhibitor drugs are medications designed to alleviate inflammation. These drugs work by suppressing the inflammatory response triggered by TNF cytokines, thereby treating various inflammatory and autoimmune conditions.

Key types of TNF inhibitor drugs available in the market include Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, and biosimilars. Humira, for instance, is a TNF blocker that diminishes the effects of substances in the body responsible for inflammation. These medications are administered via subcutaneous or intravenous injection routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are prescribed for conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, among others, to mitigate their symptoms and manage the underlying inflammation.

The tumor necrosis factor (TNF) inhibitor drugs market research report is one of a series of new reports from The Business Research Company that provides tumor necrosis factor (TNF) inhibitor drugs market statistics, including global market size, regional shares, competitors with a tumor necrosis factor (TNF) inhibitor drugs market share, detailed tumor necrosis factor (TNF) inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the tumor necrosis factor (TNF) inhibitor drugs industry. This tumor necrosis factor (TNF) inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor necrosis factor inhibitor drugs market size has grown marginally in recent years. It will grow from $42.22 billion in 2024 to $42.9 billion in 2025 at a compound annual growth rate (CAGR) of 1.6%. The growth in the historic period can be attributed to clinical efficacy, FDA approvals, increased disease prevalence, clinical trials and research, physician adoption and recommendations, patient demand and satisfaction.

The tumor necrosis factor inhibitor drugs market size is expected to see steady growth in the next few years. It will grow to $48.24 billion in 2029 at a compound annual growth rate (CAGR) of 3.0%. The growth in the forecast period can be attributed to emerging markets growth, regulatory changes and approvals, personalized medicine approaches, healthcare awareness and access, biological therapies advancements. Major trends in the forecast period include patient-centric solutions, real-world evidence and data, focus on safety and side effects, advanced drug delivery systems, expanded clinical applications.

The rising prevalence of autoimmune illnesses is poised to drive the growth of the tumor necrosis factor inhibitor drugs market. Autoimmune disorders, characterized by the immune system mistakenly attacking healthy human tissue, often result in inflammation, pain, and swelling. Tumor necrosis factor inhibitor drugs play a crucial role in mitigating these effects by blocking inflammation, providing relief from associated symptoms, and stabilizing the immune system. As of June 2022, the Autoimmune Association reported that 4.7 million men in the US were affected by autoimmune diseases, constituting 20% of all autoimmune disease patients. Additionally, a total of 31 million individuals in the US were reported to be suffering from 80-150 unique autoimmune diseases in 2022, with expectations of further increases in the future. Consequently, the escalating prevalence of autoimmune disorders serves as a driving force for the growth of the tumor necrosis factor inhibitor drugs market.

Rising healthcare expenditures are expected to drive the growth of the tumor necrosis factor inhibitor drug market. Healthcare expenditures refer to the total amount spent on healthcare services, products, and activities over a specific period, which can be measured on an individual, community, national, or global scale. Increased healthcare spending is often linked to better access to advanced and costly treatments, including biologic drugs such as TNF inhibitors. For example, in January 2024, the National Institutes of Health, a US-based government agency, reported that healthcare spending in the US increased by 4.1% in 2022, reaching $4.5 trillion. This growth rate was faster than the 3.2% increase noted in 2021. Therefore, the rising healthcare expenditure will contribute to the growth of the tumor necrosis factor inhibitor drug market.

Product innovations are a significant trend gaining traction in the tumor necrosis factor inhibitor drugs market. Leading companies in this market are concentrating on developing innovative products to enhance their competitive position. For example, in May 2024, Teva Pharmaceuticals, a US-based pharmaceutical firm, collaborated with Alvotech, a biotechnology company based in Luxembourg, to announce the launch of SIMLANDI (adalimumab-ryvk) injection in the U.S. This product serves as an interchangeable biosimilar to Humira for treating various conditions, including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.

Major players in the tumor necrosis factor inhibitor drug market are strategically embracing a partnership approach to create a new oral medicine for irritable bowel disease (IBD). Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits. In July 2022, SGS S.A., a Switzerland-based inspection, verification, testing, and certification service, announced a collaboration with CPI, Pharmidex, and Intract Pharma. The partnership aims to repackage the biologic medication infliximab, a tumor necrosis factor (TNF) inhibitor drug used for various inflammatory conditions, including IBD, into an oral capsule. This innovative oral delivery method for infliximab seeks to provide IBD patients with a more focused, convenient, and safer treatment option by withstanding the harsh conditions of the stomach. Intract Pharma Limited, Pharmidex Pharmaceutical Services Ltd., and CPI are all UK-based entities contributing their expertise to this collaborative effort.

In April 2022, Samsung Biologics, a prominent South Korea-based biotechnology company, successfully acquired Samsung Bioepis Co. Ltd. for a significant sum of $2.3 billion. This strategic acquisition is poised to enhance Samsung Biologics' capabilities in biosimilar development and position the company for improved performance in the realm of novel drug development. The acquisition is expected to provide Samsung Bioepis with greater autonomy and agility in its business operations. Samsung Bioepis Co. Ltd., also based in South Korea, is a leading biopharmaceutical company specializing in the production of tumor necrosis factor inhibitor drugs. The acquisition marks a significant move for Samsung Biologics to bolster its position in the biopharmaceutical industry and further its contributions to the development of vital medications in the tumor necrosis factor inhibitor drugs market.

Major companies operating in the tumor necrosis factor inhibitor drugs market include AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Samsung Bioepis Co. Ltd., Sanofi SA, Merck & Co. Inc., Boehringer Ingelheim Pharmaceuticals, Lupin Ltd., F. Hoffmann-La Roche AG, Cadila Healthcare Ltd., Aryogen Biopharma, Casi Pharmaceuticals, Celltrion Inc., Bristol-Myers Squibb, Dexa Medica, Epirus Biopharmaceuticals, Glaxosmithkline plc, Hanall Biopharma, Intas Pharmaceuticals, Leo Pharma AS, Biogen Inc.

North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the tumor necrosis factor inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tumor necrosis factor inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tumor necrosis factor (TNF) inhibitors drugs market consists of sales of enbrel, ereizi, inflectra, and renflexis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tumor necrosis factor inhibitor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tumor necrosis factor inhibitor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tumor necrosis factor inhibitor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Humira; Enbrel; Remicade; Simponi Or Simponi Aria; Cimzia; Biosimilars
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Rheumatoid Arthritis; Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Juvenile Idiopathic Arthritis; Hidradenitis Suppurativa; Other Applications
• Subsegments:
• 1) By Humira: Humira (adalimumab)
• 2) By Enbrel: Enbrel (etanercept)
• 3) By Remicade: Remicade (infliximab)
• 4) By Simponi Or Simponi Aria: Simponi (golimumab); Simponi Aria
• 5) By Cimzia: Cimzia (certolizumab pegol)
• 6) By Biosimilars: Biosimilars Of Humira; Biosimilars Of Enbrel; Biosimilars Of Remicade; Biosimilars Of Simponi; Biosimilars Of Cimzia
• Companies Mentioned: AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services Inc.; UCB S.A.; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tumor Necrosis Factor Inhibitor Drugs Market Characteristics

3. Tumor Necrosis Factor Inhibitor Drugs Market Trends And Strategies

4. Tumor Necrosis Factor Inhibitor Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tumor Necrosis Factor Inhibitor Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tumor Necrosis Factor Inhibitor Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tumor Necrosis Factor Inhibitor Drugs Market Growth Rate Analysis
• 5.4. Global Tumor Necrosis Factor Inhibitor Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tumor Necrosis Factor Inhibitor Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tumor Necrosis Factor Inhibitor Drugs Total Addressable Market (TAM)

6. Tumor Necrosis Factor Inhibitor Drugs Market Segmentation

• 6.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Humira
• Enbrel
• Remicade
• Simponi/Simponi Aria
• Cimzia
• Biosimilars
• 6.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Injection
• 6.3. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Hidradenitis Suppurativa
• Other Applications
• 6.5. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Humira, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Humira (adalimumab)
• 6.6. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Enbrel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enbrel (etanercept)
• 6.7. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Remicade, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Remicade (infliximab)
• 6.8. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Simponi Or Simponi Aria, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Simponi (golimumab)
• Simponi Aria
• 6.9. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Cimzia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cimzia (certolizumab pegol)
• 6.10. Global Tumor Necrosis Factor Inhibitor Drugs Market, Sub-Segmentation Of Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilars Of Humira
• Biosimilars Of Enbrel
• Biosimilars Of Remicade
• Biosimilars Of Simponi
• Biosimilars Of Cimzia

7. Tumor Necrosis Factor Inhibitor Drugs Market Regional And Country Analysis

• 7.1. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tumor Necrosis Factor Inhibitor Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market

• 8.1. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tumor Necrosis Factor Inhibitor Drugs Market

• 9.1. China Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 9.2. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tumor Necrosis Factor Inhibitor Drugs Market

• 10.1. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tumor Necrosis Factor Inhibitor Drugs Market

• 11.1. Japan Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 11.2. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tumor Necrosis Factor Inhibitor Drugs Market

• 12.1. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market

• 13.1. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tumor Necrosis Factor Inhibitor Drugs Market

• 14.1. South Korea Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 14.2. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market

• 15.1. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 15.2. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tumor Necrosis Factor Inhibitor Drugs Market

• 16.1. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tumor Necrosis Factor Inhibitor Drugs Market

• 17.1. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tumor Necrosis Factor Inhibitor Drugs Market

• 18.1. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tumor Necrosis Factor Inhibitor Drugs Market

• 19.1. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tumor Necrosis Factor Inhibitor Drugs Market

• 20.1. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market

• 21.1. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 21.2. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tumor Necrosis Factor Inhibitor Drugs Market

• 22.1. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tumor Necrosis Factor Inhibitor Drugs Market

• 23.1. North America Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 23.2. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tumor Necrosis Factor Inhibitor Drugs Market

• 24.1. USA Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 24.2. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tumor Necrosis Factor Inhibitor Drugs Market

• 25.1. Canada Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 25.2. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tumor Necrosis Factor Inhibitor Drugs Market

• 26.1. South America Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 26.2. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tumor Necrosis Factor Inhibitor Drugs Market

• 27.1. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tumor Necrosis Factor Inhibitor Drugs Market

• 28.1. Middle East Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 28.2. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tumor Necrosis Factor Inhibitor Drugs Market

• 29.1. Africa Tumor Necrosis Factor Inhibitor Drugs Market Overview
• 29.2. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tumor Necrosis Factor Inhibitor Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape And Company Profiles

• 30.1. Tumor Necrosis Factor Inhibitor Drugs Market Competitive Landscape
• 30.2. Tumor Necrosis Factor Inhibitor Drugs Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Tumor Necrosis Factor Inhibitor Drugs Market Other Major And Innovative Companies

• 31.1. Pfizer Inc.
• 31.2. Samsung Bioepis Co. Ltd.
• 31.3. Sanofi SA
• 31.4. Merck & Co. Inc.
• 31.5. Boehringer Ingelheim Pharmaceuticals
• 31.6. Lupin Ltd.
• 31.7. F. Hoffmann-La Roche AG
• 31.8. Cadila Healthcare Ltd.
• 31.9. Aryogen Biopharma
• 31.10. Casi Pharmaceuticals
• 31.11. Celltrion Inc.
• 31.12. Bristol-Myers Squibb
• 31.13. Dexa Medica
• 31.14. Epirus Biopharmaceuticals
• 31.15. Glaxosmithkline plc

32. Global Tumor Necrosis Factor Inhibitor Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tumor Necrosis Factor Inhibitor Drugs Market

34. Recent Developments In The Tumor Necrosis Factor Inhibitor Drugs Market

35. Tumor Necrosis Factor Inhibitor Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Tumor Necrosis Factor Inhibitor Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tumor Necrosis Factor Inhibitor Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tumor Necrosis Factor Inhibitor Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer